Trial abstracts in the registry — page 13
700 documents of type trial abstract.
Documents
-
Phase 1 ascending dose, phase 1 study of Semaglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low28 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low27 Sep 2023 -
Observational, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low25 Sep 2023 -
Randomised crossover, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low24 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of AOD-9604 in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low23 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of LL-37 in wound healing over as stated in the parent protocol. The Institute holds no reported primary…
Very low23 Sep 2023 -
Single-arm open-label, phase 2 study of Kisspeptin-10 in gh axis randomising 60 participants over single cycle. Primary result: Maturation achieved with a lower reported…
Low22 Sep 2023 -
Phase 1 ascending dose, phase 1 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low22 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low22 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Kisspeptin-10 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low22 Sep 2023 -
Single-arm open-label, phase 2 study of SS-31 (elamipretide) in hfpef over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low22 Sep 2023 -
Observational, phase 2 study of Kisspeptin-10 in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low21 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in sleep apnoea and obesity randomising 359 participants over 32 weeks. Primary result…
Moderate20 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing randomising 30 participants over 12 weeks. Primary result: No significant…
Low19 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in type 2 diabetes and obesity over as stated in the parent…
Very low19 Sep 2023 -
Single-arm open-label, phase 1 study of GHRP-6 in gh axis over open-label extension of the parent trial. The Institute holds no reported primary result for this record…
Very low18 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low18 Sep 2023 -
Single-arm open-label, phase 3 study of Thymosin alpha-1 in immune modulation over open-label extension of the parent trial. The Institute holds no reported primary…
Very low18 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Exenatide in cardiovascular over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low17 Sep 2023 -
Phase 1 ascending dose, phase 1 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low17 Sep 2023 -
Phase 1 ascending dose, phase 1 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low16 Sep 2023 -
Randomised crossover, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low16 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tesamorelin in lipodystrophy randomising 412 participants over 26 weeks. Primary result: Mean change −15.2…
Moderate15 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low15 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of GHRP-2 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low15 Sep 2023 -
Single-arm open-label, phase 3 study of Dulaglutide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low15 Sep 2023 -
Observational, phase 3 study of Liraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low15 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported…
Very low15 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low14 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity and prediabetes randomising 304 participants over 104 weeks. Primary result: Mean…
High13 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Orforglipron in type 2 diabetes randomising 383 participants over 26 weeks. Primary result: Reduction of…
Moderate12 Sep 2023 -
Single-arm open-label, phase 2 study of Thymosin beta-4 in wound healing over open-label extension of the parent trial. The Institute holds no reported primary result…
Very low12 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of SS-31 (elamipretide) in mitochondrial disease over as stated in the parent protocol. The Institute holds…
Very low12 Sep 2023 -
Observational, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low12 Sep 2023 -
Single-arm open-label, phase 3 study of Teduglutide in mucosal barrier randomising 88 participants over 24 months. Primary result: Reductions were maintained during…
Moderate11 Sep 2023 -
Single-arm open-label, phase 3 study of Liraglutide in prediabetes and obesity over open-label extension of the parent trial. The Institute holds no reported primary…
Very low11 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low11 Sep 2023 -
Single-arm open-label, phase 3 study of Semaglutide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low11 Sep 2023 -
Phase 1 ascending dose, phase 1 study of AOD-9604 in knee osteoarthritis over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low11 Sep 2023 -
Single-arm open-label, phase 3 study of Pramlintide in type 1 diabetes (adjunct) over open-label extension of the parent trial. The Institute holds no reported primary…
Very low11 Sep 2023
page 13 of 18